Exciting lineup of events showcasing
real-world evidence of improved outcomes and what the future holds
for Omnipod’s tubeless automated insulin delivery
Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the
global leader in tubeless insulin pump technology with its Omnipod
brand of products, today announced an exciting lineup of events and
product developments that will be discussed at the American
Diabetes Association (ADA) 83rd Scientific Sessions in San Diego,
California, including new real-world evidence (RWE) of improved
outcomes and optimization of care using the Omnipod 5 Automated
Insulin Delivery System (Omnipod 5).
“Insulet’s flagship product, Omnipod 5, is having an incredible
impact on people with diabetes, including improved glycemic
outcomes and better quality of life,” said Jim Hollingshead,
Insulet President and CEO. “We are thrilled with the opportunity to
present real-world evidence from the first year on Omnipod 5 in the
U.S., and further educate diabetes clinicians on how they can
improve care for their patients using our tubeless automated
insulin delivery technology.”
The Company also announced two updates related to Omnipod 5. In
order to provide smartphone control for customers who use iOS
mobile technology, Insulet has submitted the Omnipod 5 App for
iPhone to the FDA for 510(k) clearance. The user interface has been
enhanced to align with the iOS operating system, and a new Custom
Food feature has been added to the Omnipod 5 App for iPhone.
Additionally, progressing with the Company's goal to provide
Omnipod 5 users with sensor of choice, Insulet will soon begin
enrollment for the clinical study of Omnipod 5 with the integration
of the Abbott FreeStyle Libre 2 sensor. The study will recruit up
to 200 participants with type 1 diabetes in both the adult and
pediatric age groups in the United Kingdom, France, and Belgium.
The study is intended to demonstrate superior efficacy with Omnipod
5 compared to multiple daily injections, as measured by glycated
hemoglobin.
Insulet representatives will discuss these plans for Omnipod 5
future innovations at ADA.
Clinical Presentations
The Company will kick off ADA with a live presentation on
Friday, June 23 at 3:15 p.m. PT with Dr. Rayhan Lal, Assistant
Professor of Medicine and Pediatrics, Divisions of Endocrinology,
Stanford University presenting “Real-World Glycemic Outcomes
of 36,634 Adults with Type 1 Diabetes Using the Omnipod 5 Automated
Insulin Delivery (AID) System with Cloud-Based Data
Management.”
Additionally, Insulet will share poster presentations with
real-world evidence, including a poster demonstrating improved
outcomes for children and adolescents with type 1 diabetes using
the Omnipod 5 System. These events will build upon Insulet’s first
release of Omnipod 5 RWE presented at the Advanced Technologies
& Treatments for Diabetes (ATTD) in Berlin, Germany earlier
this year, with evidence from over 55,000 individuals across all
age groups to be shared at ADA.
Other poster presentations will convey data related to glycemic
and quality of life benefits with the Omnipod DASH® System with a
total of seven presentations at ADA (a full schedule is included
below).
Product Theater: One Year of Omnipod 5: Real World Learnings
for Optimized Care
Attendees are invited to attend a Product Theater on Sunday,
June 25 at 10:15 a.m. PT where Insulet will reflect on the impact
Omnipod 5 has had on patients and practices over one year since it
was released and lead a discussion on patient selection for
AID.
This program will be led by Dr. Trang Ly, Insulet Senior Vice
President and Medical Director. Dr. Ly will be joined by Dr. Anne
Peters, Professor of Clinical Medicine, Keck School of Medicine,
University of Southern California and Dr. Jennifer Sherr, Professor
of Pediatrics, Pediatric Endocrinology, Yale University School of
Medicine.
“It is critical to understand how this technology is being used
by adult populations across all demographics in the real world,”
said Dr. Peters, who will relay strategies for utilizing this RWE
data to improve care in diverse populations. “I’ve seen first-hand
how Omnipod 5 is having a positive impact on diverse populations in
the U.S. and translating key learnings into strategies for care
will have a lasting effect on patients and clinicians
worldwide.”
Attendees can pre-register for this event and other Insulet
programs here.
Exhibit Hall Activities and Programs
This year’s booth will offer an impressive number of
opportunities for education and engagement across the global
Omnipod portfolio:
- Live Podcast Interviews: There will be live recordings
of the Beyond the Bolus Podcast featuring Dr. Anita Swamy,
discussing the role of diabetes technology in pediatric
transitions, and Dr. Viral Shah joined by Dexcom Medical Science
Liaison, Cher Pastore on having a tech-first mindset.
- Educational Sessions: On Saturday and Sunday at 1:00
p.m. PT, Insulet’s Jennifer Boyd, MMSc, PA-C, CDCES, will host
education sessions detailing Omnipod 5’s algorithm functionality
and best practices for initiation and optimization using a new
patient case study each day.
- Special Gifts: Insulet is offering visitors a free
professional headshot and refreshments after participating in an
educational session and completing a brief survey.
- Learning Bytes: Join Insulet’s ADA Learning Byte on
Saturday, June 24 from 11:00 – 11:20 a.m. PT on the exhibit floor
where Dr. Greg Forlenza, MD and Cari Berget, MPH, RN, CDCES from
the Barbara Davis Center will relay valuable insights on care
strategies for Omnipod 5 in the pediatric population.
Schedule of Presentations
The following is the full schedule of Insulet’s posters and
presentations:
Oral Presentation:
Friday, June 23, 3:15 – 3:30 p.m. PT (Room 29)
57-OR Real-World Glycemic Outcomes of
36,634 Adults with Type 1 Diabetes Using the Omnipod 5 Automated
Insulin Delivery (AID) System with Cloud-Based Data Management
with Dr. Rayhan Lal
Poster Presentations:
Saturday, June 24, 11:30 – 12:30 p.m. PT (Poster Halls B-C)
683-P Lived Experiences of Using Omnipod
DASH System Among Australians with Type 1 Diabetes: A Qualitative
Study with Dr. Yee Wen Kong
109-LB Quality of Life Benefits for
Insulin-Using Adults with Type 2 Diabetes after Six Months of Pump
Therapy: A Quasi-Experimental Approach with Dr. William
Polonsky
Sunday, June 25, 11:30 – 12:30 p.m. PT (Poster Halls B-C)
898-P Real-World Glycemic Outcomes of
18,516 Children and Adolescents with Type 1 Diabetes Using the
Omnipod 5 Automated Insulin Delivery (AID) System with Cloud-Based
Data Management with Dr. Jennifer Sherr
897-P Real-World Glycemic Outcomes of
4,446 Adults with Type 2 Diabetes Using the Omnipod 5 Automated
Insulin Delivery (AID) System with Cloud-Based Data Management
with Dr. Anne Peters
917-P Treatment Satisfaction with Omnipod
DASH System vs. Usual Care in Adults with Type 1 Diabetes in
Australia with Dr. Yee Wen Kong
907-P Glycaemic Outcomes Associated with
Omnipod DASH Use in the Real-World: Results from the Association of
British Clinical Diabetologists (ABCD) Omnipod Worldwide Audit
with Dr. Thomas Crabtree
About Insulet Corporation:
Insulet Corporation (NASDAQ: PODD), headquartered in
Massachusetts, is an innovative medical device company dedicated to
simplifying life for people with diabetes and other conditions
through its Omnipod product platform. The Omnipod Insulin
Management System provides a unique alternative to traditional
insulin delivery methods. With its simple, wearable design, the
tubeless disposable Pod provides up to three days of non-stop
insulin delivery, without the need to see or handle a needle.
Insulet’s flagship innovation, the Omnipod® 5 Automated Insulin
Delivery System, integrates with a continuous glucose monitor to
manage blood sugar with no multiple daily injections, zero
fingersticks, and can be controlled by a compatible smartphone or
Omnipod 5 Controller. Insulet also leverages the unique design of
its Pod by tailoring its Omnipod technology platform for the
delivery of non-insulin subcutaneous drugs across other therapeutic
areas. For more information, please visit: insulet.com and
omnipod.com.
Forward-Looking Statement:
This press release may contain forward-looking statements
concerning Insulet's expectations, anticipations, intentions,
beliefs, or strategies regarding the future. These forward-looking
statements are based on its current expectations and beliefs
concerning future developments and their potential effects on
Insulet. There can be no assurance that future developments
affecting Insulet will be those that it has anticipated. These
forward-looking statements involve a number of risks, uncertainties
(some of which are beyond its control) or other assumptions that
may cause actual results or performance to be materially different
from those expressed or implied by these forward-looking
statements, and other risks and uncertainties described in its
Annual Report on Form 10-K, which was filed with the Securities and
Exchange Commission on February 24, 2023 in the section entitled
"Risk Factors," and in its other filings from time to time with the
Securities and Exchange Commission. Should one or more of these
risks or uncertainties materialize, or should any of its
assumptions prove incorrect, actual results may vary in material
respects from those projected in these forward-looking statements.
Insulet undertakes no obligation to publicly update or revise any
forward-looking statements.
©2023 Insulet Corporation. Omnipod, Omnipod DASH and Omnipod 5
are trademarks or registered trademarks of Insulet Corporation. All
rights reserved. All other trademarks are the property of their
respective owners. The use of third-party trademarks does not
constitute an endorsement or imply a relationship or other
affiliation.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230622267884/en/
Investor Relations: Deborah R. Gordon Vice President,
Investor Relations (978) 600-7717 dgordon@insulet.com
Media: Angela Geryak Wiczek Senior Director, Corporate
Communications (978) 932-0611 awiczek@insulet.com
Insulet (NASDAQ:PODD)
Gráfico Histórico do Ativo
De Abr 2024 até Mai 2024
Insulet (NASDAQ:PODD)
Gráfico Histórico do Ativo
De Mai 2023 até Mai 2024